Published in Br J Cancer on October 26, 2010
Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells. PLoS One (2011) 0.94
The contributions of HIF-target genes to tumor growth in RCC. PLoS One (2013) 0.92
Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One (2011) 0.91
Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer. Am J Pathol (2013) 0.86
EGLN3 inhibition of NF-κB is mediated by prolyl hydroxylase-independent inhibition of IκB kinase γ ubiquitination. Mol Cell Biol (2013) 0.83
In vitro microtumors provide a physiologically predictive tool for breast cancer therapeutic screening. PLoS One (2015) 0.83
PHD3-mediated prolyl hydroxylation of nonmuscle actin impairs polymerization and cell motility. Mol Biol Cell (2014) 0.82
Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma. J Cancer Res Clin Oncol (2014) 0.81
RanBPM expression regulates transcriptional pathways involved in development and tumorigenesis. Am J Cancer Res (2012) 0.80
Prolyl-4-hydroxylase 3 (PHD3) expression is downregulated during epithelial-to-mesenchymal transition. PLoS One (2013) 0.80
Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions. Oncotarget (2015) 0.80
Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis. Int J Mol Sci (2015) 0.79
Prolyl-hydroxylase 3: Evolving Roles for an Ancient Signaling Protein. Hypoxia (Auckl) (2013) 0.79
Construction of a recombinant eukaryotic expression vector containing PHD3 gene and its expression in HepG2 cells. J Exp Clin Cancer Res (2012) 0.79
Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR. Nat Commun (2014) 0.79
Function and expression of prolyl hydroxylase 3 in cancers. Arch Med Sci (2013) 0.79
Hypoxia inducible prolyl hydroxylase PHD3 maintains carcinoma cell growth by decreasing the stability of p27. Mol Cancer (2015) 0.78
Potential regulation of glioma through the induction of apoptosis signaling via Egl-9 family hypoxia-inducible factor 3. Oncol Lett (2016) 0.77
Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancreatic ductal adenocarcinoma. J Gastroenterol (2014) 0.76
Effect of stable transfection with PHD3 on growth and proliferation of HepG2 cells in vitro and in vivo. Int J Clin Exp Med (2014) 0.76
Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget (2016) 0.75
Prolyl hydroxylase domain protein 3 and asparaginyl hydroxylase factor inhibiting HIF-1 levels are predictive of tumoral behavior and prognosis in hepatocellular carcinoma. Oncotarget (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 23.83
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 19.75
Purification and characterization of hypoxia-inducible factor 1. J Biol Chem (1995) 8.53
Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16
The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ (2008) 4.31
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell (2005) 3.51
Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol (1994) 3.30
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A (1992) 2.76
Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J (2004) 1.90
The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res (2006) 1.75
Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas (2003) 1.40
Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol (1999) 1.38
HIF hydroxylation and cellular oxygen sensing. Biol Chem (2004) 1.32
Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv Exp Med Biol (2005) 1.30
Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem (2007) 1.24
Hypoxia and cancer. Cancer Metastasis Rev (2007) 1.23
The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg (2005) 1.11
Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res (2004) 1.07
Expression of key hypoxia sensing prolyl-hydroxylases PHD1, -2 and -3 in pancreaticobiliary cancer. Histopathology (2010) 0.97
Human PRP19 interacts with prolyl-hydroxylase PHD3 and inhibits cell death in hypoxia. Exp Cell Res (2010) 0.97
Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid. Pancreas (2003) 0.97
Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia (2007) 0.96
PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer. Cancer (2007) 0.86
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 19.75
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 5.75
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell (1996) 4.74
Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg (2004) 3.90
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg (2001) 2.94
IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol (2000) 2.93
Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas (2004) 2.85
Acute necrotizing pancreatitis: treatment strategy according to the status of infection. Ann Surg (2000) 2.73
Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. J Neurosci Res (1996) 2.67
Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene (1997) 2.58
Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest (1992) 2.54
Pancreatic fistula after pancreatic head resection. Br J Surg (2000) 2.44
Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg (1992) 2.38
Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood (1999) 2.35
Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol (2006) 2.33
Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res (2001) 2.24
The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest (1998) 2.22
Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res (1993) 2.15
Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res (1993) 2.08
Neuroimmune appendicitis. Lancet (1999) 2.05
Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol (1993) 2.05
[The diagnostic value of the amino acid absorption test in detection of a disorder of exocrine pancreatic function]. Z Gastroenterol (1992) 2.02
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
Carcinoid of the ampulla of Vater. Clinical characteristics and morphologic features. Cancer (1994) 1.97
Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg (2007) 1.92
Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy. Am J Surg (2001) 1.87
VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer (2008) 1.84
Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg (2011) 1.82
Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer (1999) 1.81
Biosynthesis of the first component of complement by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1 subunits. J Immunol (1978) 1.79
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
ESPEN guidelines on nutrition in acute pancreatitis. European Society of Parenteral and Enteral Nutrition. Clin Nutr (2002) 1.75
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood (1995) 1.75
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res (1997) 1.74
Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol (1974) 1.69
Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol (1994) 1.69
Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res (2001) 1.67
Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer (1995) 1.67
The role of infection in acute pancreatitis. Gut (1999) 1.66
Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation (2001) 1.64
Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human. Hum Mol Genet (2006) 1.63
The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene (1999) 1.63
Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Circ Res (2001) 1.60
Antibody-independent interaction of the first component of complement with Gram-negative bacteria. Infect Immun (1978) 1.60
KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res (1996) 1.59
Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci U S A (2000) 1.55
Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood (2001) 1.54
Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun (1998) 1.52
Randomized trial of duodenum-preserving pancreatic head resection versus pylorus-preserving Whipple in chronic pancreatitis. Am J Surg (1995) 1.52
A pancreatic cancer-specific expression profile. Oncogene (1996) 1.50
Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg (2008) 1.50
Immune cell infiltration and growth-associated protein 43 expression correlate with pain in chronic pancreatitis. Gastroenterology (1997) 1.49
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer (1997) 1.47
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut (2001) 1.46
Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun (1981) 1.43
Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg (2005) 1.42
Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol (2003) 1.42
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas (1999) 1.41
Randomized controlled trial of ultrasonic dissection versus standard surgical technique in open left hemicolectomy or total gastrectomy. Br J Surg (2011) 1.41
Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol (2006) 1.41
A 66-kilodalton heat shock protein of Salmonella typhimurium is responsible for binding of the bacterium to intestinal mucus. Infect Immun (1992) 1.41
Porcelain gallbladder is not associated with gallbladder carcinoma. Am Surg (2001) 1.40
Importance of the duodenal passage and pouch volume after total gastrectomy and reconstruction with the Ulm pouch: prospective randomized clinical study. World J Surg (1996) 1.40
Risk of malignancy in resected cystic tumors of the pancreas < or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. J Gastrointest Surg (2007) 1.39
Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer (2000) 1.39
NOTES for the cardia: antireflux therapy via transluminal access. Endoscopy (2010) 1.38
Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol (1999) 1.38
Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen (2001) 1.37
Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer (2000) 1.37
The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Lett (2001) 1.37
Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology (1999) 1.36
Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res (1993) 1.36
Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem (1996) 1.35
Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann Surg (1999) 1.34
Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol (1999) 1.33
Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res (1994) 1.32
Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. J Neurosci Res (1996) 1.32
Herpes simplex virus sepsis and acute liver failure. Clin Transplant (2009) 1.32
Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology (1992) 1.31
Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol (1998) 1.30
Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg (1999) 1.27
Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer (1995) 1.26
Cytotoxic cells are activated in cellular infiltrates of alcoholic chronic pancreatitis. Gastroenterology (1997) 1.26
Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol (2000) 1.25
Balance of expression of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in chronic pancreatitis. Z Gastroenterol (1994) 1.25
Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem (2007) 1.24
2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology (1995) 1.24
Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res (1994) 1.23
Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation (1997) 1.23
[Measurement of complement with a microliter method]. Z Med Mikrobiol Immunol (1969) 1.22
Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int (2000) 1.20
Primary duodenal adenocarcinoma: a 40-year experience. Arch Surg (2000) 1.20
Solid and papillary epithelial neoplasms of the pancreas: aggressive resection for cure. Am Surg (2001) 1.20
Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut (2005) 1.20